Ipragliflozin, an SGLT2 Inhibitor, Reduces Body Weight and Fat Mass, but not Muscle Mass, in Japanese Type 2 Diabetic Patients Treated with Insulin: A Randomized Clinical Trial.
利用統計を見る
Journal of Diabetes Investigation. 2019 Jul;10(4):1012-1021.
"Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial."
Ipragliflozin, an SGLT2 Inhibitor, Reduces Body Weight and Fat Mass, but not Muscle Mass, in Japanese Type 2 Diabetic Patients Treated with Insulin: A Randomized Clinical Trial.
h833
(1.09MB)
